Arkolith/Insider Trading/NRIX/Form 4

van Houte Hans

Chief Financial OfficerNurix Therapeutics, Inc. (NRIX) · full profile →Form 4 · filed Apr 30, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$40K
Net Open-Market Flow
-$40K
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 30, 2026Option exercise(M)2K—$047K
Apr 30, 2026Option exercise(M)4K—$051K
Apr 30, 2026Option exercise(M)3K—$054K
Apr 30, 2026Sell(S)2K$16.65$40K52K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 30, 2026Option exercise(M)2K—$00
Apr 30, 2026Option exercise(M)4K—$015K
Apr 30, 2026Option exercise(M)3K—$023K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001817217-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML